Citadel Advisors
MANE

Citadel Advisors’s Veradermics Inc MANE Stock Holding History

Citadel Advisors’s Portfolio MANE Stock Details MANE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115M Buy
+1,825,672
New +$92.1M 0.02% 724

Other funds holding MANE

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's MANE Position: Q1 2026 in Review

Citadel Advisors opened a new position in Veradermics Inc (MANE) in Q1 2026: 1,825,672 shares worth $115M. The stake represents 0.02% of the portfolio and ranks #724 among its holdings.

81 funds tracked by Wall St. Rank hold MANE as of Q1 2026.

  • Citadel Advisors held 1,825,672 shares of Veradermics Inc worth $115M as of Q1 2026.
  • Veradermics Inc was a new Citadel Advisors position in Q1 2026.
  • Veradermics Inc made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #724 holding.
  • 81 funds tracked by Wall St. Rank held Veradermics Inc as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.